Allorion Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
A biotech with an integrated platform developing novel small-molecule therapies for cancer and immune disorders.
OncologyImmunology
Technology Platform
An integrated drug discovery platform incorporating allosteric inhibition, targeted protein degradation, and other modalities for novel small-molecule development.
Funding History
1Total raised:$50M
Venture$50M
Opportunities
Its multi-modality platform could generate a diversified pipeline with multiple shots on goal for high-value targets in large markets.
Risk Factors
Operational complexity in managing multiple advanced technology stacks and the challenge of prioritizing resources across a potentially broad pipeline.
Competitive Landscape
Faces competition from both modality-specific leaders (e.g., in PROTACs) and large, fully-integrated biopharmaceutical companies with vast resources.